As the glycoprotein @entity1427 /IIIa receptor is the final common pathway in @entity1423 , antagonists of this receptor cause a profound inhibition of aggregation induced by any agonist. The short-term efficacy and safety of @entity1427 /IIIa antagonists in @entity1 undergoing coronary angioplasty was demonstrated with @entity19 7E3 Fab, but this antibody was immunogenic. Abciximab is a chimeric human-mouse monoclonal antibody that is less immunogenic. The first major trial with a @entity1427 /IIIa antagonist was the EPIC trial with abciximab, which showed that abciximab reduced the @entity63 complications of @entity301 and atherectomy in high-risk @entity1 , but increased the risk of @entity548 . Subsequent studies showed that using less concurrent heparin reduced @entity548 . Abciximab also reduced the rate of revascularization. Further studies have shown that the benefits of abciximab extended to all @entity1 undergoing angioplasty (EPILOG), including @entity1 with @entity1459 (CAPTURE) and acute @entity583 (RAPPORT). Clinical trials with eptifibatide and tirofiban have failed to demonstrate benefit, at the doses used, in angioplasty. Abciximab and eptifibatide, but not oral xemilofiban, improve the safety of the coronary stenting procedure. Short-term intravenous treatment with @entity50600 , eptifibatide or @entity6541 is beneficial in @entity1187 ( @entity1459 , non-Q wave @entity583 ). Orally active @entity1427 /IIIa antagonists are being developed for use in @entity1187 and @entity583 . However, no benefit has been shown with lefradafiban in @entity1187 and sibrafiban and orbofiban are harmful. Eptifibatide, lamifiban and abciximab improve coronary patency in @entity583 , and long- term trials of @entity1427 /IIIa antagonists are being conducted in acute @entity583 . Abciximab can cause @entity882 , and all the @entity1427 / IIIa antagonists increase the incidence of @entity548 , but there is no excess of @entity932 . (c) 2001 Prous Science. All rights reserved.

Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without XXXX ?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity19 :: ('10090', 'Species') :: ['murine'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary balloon angioplasty'] @entity6541 :: ('CHEBI:9605', 'Chemical') :: ['tirofiban'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity50600 :: ('MESH:C084062', 'Chemical') :: ['lamifiban'] @entity1427 :: ('3674', 'Gene') :: ['GPIIb'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']
@entity548 :: (MESH:D006470,Disease) :: ['bleeding']
